Posters

Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery, a comparative study

Poster Details

First Author: P.Ntonti GREECE

Co Author(s): E. Panagiotopoulou   A. Mehmet   M. Gkika   D. Dardabounis   G. Labiris        

Abstract Details

Purpose:

Recent artificial tear preparations have provided 0.2% concentration of sodium hyaluronate. However, no published data exist on their potential superiority against 0.1% in alleviating dry-eye-disease symptoms in cataract extraction surgery. The purpose of this study is to compare the impact of these two artificial tear preparations on postoperative discomfort following cataract extraction surgery.

Setting:

Department of Ophthalmology, University Hospital of Alexandroupolis

Methods:

: 180 patients populated 2 groups: Study group (SG) received fixed combination of tobramycin and dexamethasone (FCTD) quid for 3 weeks and, additionally 0.2 % sodium hyaluronate quid, for 6 weeks, Control group (CG) received FCTD quid for 3 weeks and, additionally 0.1 % sodium hyaluronate quid, for 6 weeks. The following indexes were evaluated: 1) Subjective discomfort index (SDI) which derived by: a) foreign body sensation (FBS), b) blinking discomfort (BD), c) stinging sensation (SS), d) tearing sensation (TS), 2) Tear break-up time (TBUT), 3) Schirmer’s test, 4) Central corneal thickness (CCT) and, 4) Central Corneal Sensitivity (CCS).

Results:

Both groups showed reduced CCS values at all postoperative examination points, however SG participants had significantly better CCS (all p<0.05). SG had better TBUT times than CG at the 3rd (p=0.03) and 6th examination points (p=0.04). Moreover, SG had better SDI scores at the 3rd (SDI=9.26±0.55) and 6th week (SDI=9.47±0.48) than CG participants (p=0.03 & p<0.01, respectively).

Conclusions:

The increased 0.2 % sodium hyaluronate concentration in the artificial tears provided in the COMOD® device seems to address dry-eye-disease symptoms better in patients who underwent phacoemulsification surgery than the 0.1% concentration.

Financial Disclosure:

None